Exicure (NASDAQ:XCUR) Downgraded by Zacks Investment Research

Exicure (NASDAQ:XCURGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Exicure Inc. is a clinical-stage biotechnology company. It is engaged in developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid technology. Exicure Inc. is based in IL, United States. “

Shares of XCUR stock opened at $0.12 on Thursday. Exicure has a 1-year low of $0.10 and a 1-year high of $1.98. The stock’s fifty day moving average price is $0.19 and its 200 day moving average price is $0.33. The company has a market cap of $15.10 million, a price-to-earnings ratio of -0.17 and a beta of 1.60.

Exicure (NASDAQ:XCURGet Rating) last announced its earnings results on Friday, March 25th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. The business had revenue of $2.12 million for the quarter. Sell-side analysts predict that Exicure will post -0.15 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. UBS Group AG lifted its position in Exicure by 184.9% during the 3rd quarter. UBS Group AG now owns 29,409 shares of the company’s stock worth $35,000 after acquiring an additional 19,087 shares during the period. Morgan Stanley lifted its position in Exicure by 34.8% during the 2nd quarter. Morgan Stanley now owns 49,425 shares of the company’s stock worth $74,000 after acquiring an additional 12,751 shares during the period. HighTower Advisors LLC lifted its position in Exicure by 48.0% during the 3rd quarter. HighTower Advisors LLC now owns 73,867 shares of the company’s stock worth $88,000 after acquiring an additional 23,952 shares during the period. Raymond James & Associates lifted its position in Exicure by 20.8% during the 3rd quarter. Raymond James & Associates now owns 75,500 shares of the company’s stock worth $91,000 after acquiring an additional 13,000 shares during the period. Finally, Sigma Planning Corp lifted its position in Exicure by 898.2% during the 4th quarter. Sigma Planning Corp now owns 169,700 shares of the company’s stock worth $34,000 after acquiring an additional 152,700 shares during the period. 41.68% of the stock is owned by institutional investors.

Exicure Company Profile (Get Rating)

Exicure, Inc, a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen SA to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.

See Also

Get a free copy of the Zacks research report on Exicure (XCUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.